公开(公告)号：US11266602B2

公开(公告)日：2022-03-08

申请号：US16098619

申请日：2017-05-15

Applicant: Infectious Disease Research Institute ,  University of Virginia Patent Foundation

Inventor： Christopher B. Fox ,  Susan S. Lin ,  Darrick Carter ,  Neal Van Hoeven ,  Mayuresh M. Abhyankar ,  William A. Petri

IPC: A61K9/127 ,  A61K31/739 ,  A61K39/39 ,  A61K39/00

Abstract: Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.

公开(公告)号：US20220017578A1

公开(公告)日：2022-01-20

申请号：US17367812

申请日：2021-07-06

Applicant: Infectious Disease Research Institute

Inventor： Steven G. REED ,  Rhea N. COLER ,  Gregory C. IRETON ,  Sylvie BERTHOLET

IPC: C07K14/35 ,  A61K39/04 ,  C07K14/285 ,  G01N33/569 ,  G01N33/68

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sr) antigens, and polynucleotides encoding such compositions and fusion proteins, The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

公开(公告)号：US20210069323A1

公开(公告)日：2021-03-11

申请号：US16855622

申请日：2020-04-22

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/39 ,  A61K9/107 ,  A61K39/00 ,  A61K39/35 ,  A61K45/06 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US20200246268A1

公开(公告)日：2020-08-06

申请号：US16620160

申请日：2018-06-07

Applicant: PAI Life Sciences Inc. ,  Infectious Disease Research Institute ,  Research Triangle Institute

Inventor： Darrick CARTER ,  Anthony James HICKEY ,  Phillip Gregory DURHAM ,  Ragan PITNER

IPC: A61K9/14 ,  A61K31/7076 ,  A61K38/12 ,  A61K9/00

Abstract: Capreomycin sulfate and CPZEN-45, which act in non-identical manners to treat tuberculosis infection, are combined into particles by spray drying thereby giving an intimate mixture for combination drug therapy. The spray dried combination powder is prepared in an aerodynamic particle size range (such as 1-5 μm) suitable for pulmonary delivery when delivered from an inhaler.

公开(公告)号：US20200085757A1

公开(公告)日：2020-03-19

申请号：US16098617

申请日：2017-05-17

Applicant: Infectious Disease Research Institute

Inventor： Neal Van Hoeven ,  Traci Mikasa ,  Christopher B. Fox ,  Anwar Ahniyaz ,  Mark T. Orr ,  Amit Khandhar

IPC: A61K9/51 ,  A61K9/127 ,  A61K39/39

Abstract: Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle N ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

公开(公告)号：US20200038498A1

公开(公告)日：2020-02-06

申请号：US16126285

申请日：2018-09-10

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Rhea N. Coler

IPC: A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K39/39 ,  A61K45/06

Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.

公开(公告)号：US09909114B2

公开(公告)日：2018-03-06

申请号：US14780504

申请日：2014-03-28

Applicant: Infectious Disease Research Institute

Inventor： Malcolm Duthie ,  Jeff Guderian ,  Steven G. Reed

IPC: C12N9/24 ,  A61K39/008 ,  C12N9/10 ,  G01N33/569

CPC classification number: C12N9/2497 ,  A61K39/008 ,  C12N9/1007 ,  C12Y201/01041 ,  C12Y302/02001 ,  G01N33/56905 ,  G01N2333/44 ,  G01N2469/20 ,  Y02A50/41

Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising Leishmania antigens as well as polynucleotides encoding such polypeptides.

公开(公告)号：US20160324783A1

公开(公告)日：2016-11-10

申请号：US15108773

申请日：2014-12-29

Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE

Inventor： Christopher B. FOX ,  Thomas S. VEDVICK ,  Lucien BARNES V. ,  Ryan M. KRAMER ,  Steven G. REED

IPC: A61K9/19 ,  A61K47/22 ,  A61K47/26 ,  A61K47/10 ,  A61K39/04 ,  A61K39/39

CPC classification number: A61K9/19 ,  A61K39/00 ,  A61K39/04 ,  A61K39/39 ,  A61K47/10 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/55572

Abstract: The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.

Abstract translation: 本发明提供了耐热冻干制剂，包括用于诱导或增强免疫应答的疫苗和药物组合物及其使用方法。 冻干制剂通常包含抗原和/或佐剂，可代谢的油和成饼赋形剂。

公开(公告)号：US20160058860A1

公开(公告)日：2016-03-03

申请号：US14849212

申请日：2015-09-09

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/39 ,  A61K39/008 ,  A61K45/06 ,  A61K39/00 ,  C12N7/00 ,  A61K39/145 ,  A61K39/04

CPC classification number: A61K39/39 ,  A61K39/0005 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145 ,  A61K45/06 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/57 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16071 ,  Y02A50/41 ,  Y02A50/412

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US20150335736A1

公开(公告)日：2015-11-26

申请号：US14581062

申请日：2014-12-23

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/39 ,  A61K39/04 ,  A61K39/008 ,  A61K9/107 ,  A61K39/145

CPC classification number: A61K39/39 ,  A61K9/107 ,  A61K39/0011 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145 ,  A61K39/35 ,  A61K45/06 ,  A61K2039/55511 ,  A61K2039/55572 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/396 ,  Y02A50/41 ,  Y02A50/491

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

Abstract translation: 基于在基本上均匀形式提供的合成的吡喃葡萄糖基脂质佐剂（GLA）中发现有用的免疫佐剂性质，公开了组合物和方法，包括用于诱导或增强免疫应答的疫苗和药物组合物。 在化学上，合成的GLA提供了从批次到批次的一致的疫苗组分，而不会损害天然产物佐剂的污染物或活性的波动。 还提供了疫苗和药物组合物，其包括GLA和抗原，Toll样受体（TLR）激动剂，辅助佐剂和载体如药物载体中的一种或多种。